SCHEMBL14729154

SCHEMBL14729154

Cc1ccc(OC(=O)N2CCC(Oc3nc4ccc(C5CCN(S(=O)(=O)CCC(C)(C)O)CC5)cc4s3)CC2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
FAAH O00519 1/20 0.35
ACACB O00763 3/20 0.35
PDE4B Q07343 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
LMNA P02545 2/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
NAMPT P43490 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728958 0.93 FAAH (0.38) FAAHACACBPDE4BTP53MAPT
SCHEMBL14729153 0.89 TLR9 (0.39) TLR9TLR8TLR7FAAHACACB
SCHEMBL14729019 0.85 ACACB (0.36) TLR9TLR8TLR7ACACBPDE4B
SCHEMBL14728962 0.85 PDE4B (0.44) PDE4BGPR119GRIN2BNPC1RAB9A
SCHEMBL14729152 0.84 GPR119 (0.39) ACACBTP53MAPTGPR119
SCHEMBL14729183 0.84 GPR119 (0.40) TLR8TLR7ACACBMAPTGPR119
SCHEMBL14728960 0.81 FAAH (0.38) FAAHPDE4BTP53MAPTLMNA
SCHEMBL14729021 0.81 GPR119 (0.36) TLR9TLR8TLR7ACACBPDE4B
SCHEMBL14729056 0.80 GPR119 (0.40) ACACBMAPTGPR119NPC1
SCHEMBL14729182 0.80 GPR119 (0.40) TLR8TLR7ACACBMAPTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS GPR119, GPR139, GPR4 TLR9 315/4885TLR8 1063/4885TLR7 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.